Latest Biotech News

A provision in the current appropriations bill would allow Medicare to cover multi‑cancer early detection (MCED) tests after FDA approval without awaiting US Preventive Services Task Force...

The National Institutes of Health announced it will end support for research using human fetal tissue, a decision that several scientists called political rather than scientific. The move affects...

Swiss company 4bases and the University of Florence launched clinical pilot studies of a nanopore sequencing‑based cytogenetics workflow, KaryoSolver, in two Italian hospitals. The pilots aim to...

Researchers unveiled camouflaged nanorobots engineered to modulate macrophage behavior within neural tissue and promote regeneration. The devices are designed to influence immune cell polarization...

The FDA approved Guardant Health’s Guardant360 CDx as a companion diagnostic to identify BRAF V600E–mutant metastatic colorectal cancer patients for Pfizer’s encorafenib (Braftovi) plus cetuximab...

Regulators signaled a new pathway for multiple myeloma drug development by issuing draft guidance that permits measurable residual disease (MRD) negativity and complete response rates to support...

Corcept Therapeutics reported a 35% reduction in risk of death when its selective glucocorticoid receptor antagonist relacorilant was added to chemotherapy in platinum‑resistant ovarian cancer,...

Bristol Myers Squibb struck a two-stage collaboration with Janux Therapeutics to develop tumor‑activated (masked) T‑cell engagers, providing $50 million upfront and potential payments pushing the...

Major pharma companies moved from one‑off asset partnerships to platform investments, signing AI platform deals with startups like Chai Discovery, Noetik and Boltz to deploy models for biologics...

Corxel Pharmaceuticals closed a $287 million financing to support global development of its oral GLP‑1 candidate, a program the company licensed from Vincentage. The round funds pivotal phase 2/3...

Swiss firm 4bases began clinical pilot studies in two Italian hospitals to validate a nanopore sequencing workflow, KaryoSolver, for real‑time detection of copy number variants (CNVs) against...

Avacta Therapeutics received FDA IND clearance for AVA‑6103, a tumor‑activated precision peptide‑drug conjugate targeting FAP, clearing the way for first‑in‑human studies in solid tumors....

A cluster of European cancer‑vaccine companies announced new financing and clinical progress: Accession, Infinitopes and Ervimmune secured fresh capital, with off‑the‑shelf and improved targeting...

The fiscal‑year appropriations bill under negotiation includes a provision to streamline Medicare coverage for FDA‑approved multi‑cancer early detection (MCED) tests, making them eligible for...

The FDA released draft guidance outlining how measurable residual disease (MRD) negativity could support accelerated approval for multiple myeloma therapies. The agency’s document, described in a...

Guardant Health won FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic to identify BRAF V600E-mutant metastatic colorectal cancer patients eligible for Pfizer's...

Corcept Therapeutics reported that adding relacorilant to chemotherapy reduced risk of death by 35% in a Phase 3 ovarian cancer study, a result the company said will shape its regulatory path...

GSK agreed to acquire Rapt Therapeutics for $2.2 billion to add ozureprubart, a long-acting anti-IgE monoclonal antibody being developed for food allergy, to its immunology portfolio. The deal...

Bristol Myers Squibb struck a collaboration with Janux Therapeutics focused on a tumor-activated T‑cell engager for solid tumors, paying $50 million upfront and committing up to $850 million in...

Corxel Pharmaceuticals raised up to $287 million in a Series D financing to advance its oral GLP‑1 receptor agonist through phase 2/3 obesity studies. The China‑founded company has shifted...